{"id":745327,"date":"2016-09-28T05:45:00","date_gmt":"2016-09-28T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/"},"modified":"2025-11-07T01:25:39","modified_gmt":"2025-11-07T06:25:39","slug":"two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/","title":{"rendered":"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016"},"content":{"rendered":"<p class=\"bwalignc\">       Results from KEYNOTE-024, which Studied KEYTRUDA Compared to        Chemotherapy in Patients with High Levels of PD-L1 Expression, and        KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy        Compared to Chemotherapy Alone in Patients Regardless of PD-L1        Expression, to be Presented     <\/p>\n<p class=\"bwalignc\">       Comprehensive Data from Merck\u2019s Industry-Leading Immuno-Oncology        Clinical Development Program to be Presented, with New Data in 12 Cancers     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that extensive data on KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, have been accepted for<br \/>\n      presentation at the European Society for Medical Oncology (ESMO) 2016<br \/>\n      Congress in Copenhagen, Denmark, Oct. 7 \u2013 11. In total, findings from 30<br \/>\n      studies in 12 cancers from Merck\u2019s industry-leading clinical development<br \/>\n      program for KEYTRUDA \u2013 both as monotherapy and in combination \u2013 will be<br \/>\n      presented at this year\u2019s ESMO. Two studies of KEYTRUDA in first-line<br \/>\n      treatment of advanced lung cancer have also been selected for<br \/>\n      presentation at the Presidential Symposium on Oct. 9: KEYNOTE-024, which<br \/>\n      studied KEYTRUDA as monotherapy compared to chemotherapy in patients<br \/>\n      whose tumors express high levels of PD-L1 (tumor proportion score of 50<br \/>\n      percent or more), and KEYNOTE-021G, which studied KEYTRUDA plus<br \/>\n      chemotherapy (carboplatin and pemetrexed) compared to chemotherapy alone<br \/>\n      in all patients with non-squamous non-small cell lung cancer (NSCLC).\n    <\/p>\n<p>\n      <b>KEYTRUDA-Related Data at the ESMO 2016 Congress<\/b>\n    <\/p>\n<p>\n      A select listing of the KEYTRUDA late-breaking and oral abstract<br \/>\n      sessions at ESMO 2016 is included below:\n    <\/p>\n<p>\n      <b>Advanced Non-Small Cell Lung Cancer (NSCLC)<\/b>\n    <\/p>\n<p>\n      At ESMO, in addition to KEYNOTE-024 and KEYNOTE-021G, which studied<br \/>\n      KEYTRUDA (pembrolizumab) in previously untreated patients whose tumors<br \/>\n      were EGFR- and ALK-negative, updated overall survival (OS) data from the<br \/>\n      phase 2\/3 KEYNOTE-010 trial will be presented; KEYNOTE-010 studied<br \/>\n      previously treated patients with advanced NSCLC whose tumors express<br \/>\n      PD-L1 (tumor proportion score of one percent or more).\n    <\/p>\n<p>\n      Additional combination data will also be presented from the phase 1b<br \/>\n      KEYNOTE-098 expansion cohort study investigating KEYTRUDA in combination<br \/>\n      with the VEGF Receptor 2 antagonist, ramucirumab (under the existing<br \/>\n      collaboration between Eli Lilly and Company and Merck).\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #LBA46_PR)<\/b> <b>Presidential Symposium: Randomized,<br \/>\n        phase 2 study of carboplatin and pemetrexed with or without<br \/>\n        pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021<br \/>\n        cohort G. <\/b>C. Langer.<b> <\/b>Sunday, October 9, 4:25 \u2013 6:20 pm<br \/>\n        CEST. Location: Copenhagen.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #LBA8_PR) Presidential Symposium: KEYNOTE-024:<br \/>\n        Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as<br \/>\n        first-line therapy for advanced NSCLC with a PD-L1 tumor proportion<br \/>\n        score (TPS) \u2265 50%.<\/b> M. Reck. Sunday, October 9, 4:25 \u2013 6:20 pm<br \/>\n        CEST. Location: Copenhagen.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #LBA48) Poster Discussion Session: Pembrolizumab (pembro)<br \/>\n        vs docetaxel (doce) for previously treated, PD-L1\u2013expressing NSCLC:<br \/>\n        updated outcomes of KEYNOTE-010.<\/b> R. Herbst.<b> <\/b>Sunday, October<br \/>\n        9, 2:45 \u2013 4:15 pm CEST. Location: Oslo.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #LBA38) Poster Discussion Session:<\/b> <b>Interim safety<br \/>\n        and clinical activity in patients with advanced NSCLC from a<br \/>\n        multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). <\/b>R.<br \/>\n        Herbst. Monday, October 10, 9:30 \u2013 10:30 am CEST. Location: Berlin.\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Bladder Cancer<\/b>\n    <\/p>\n<p>\n      At ESMO, data investigating the first-line use of KEYTRUDA in patients<br \/>\n      with unresectable or advanced urothelial (bladder) cancer will be<br \/>\n      presented from the phase 2 KEYNOTE-052 trial; results will be featured<br \/>\n      in the official ESMO press program. This is the first presentation of<br \/>\n      data investigating KEYTRUDA in the first-line bladder cancer treatment<br \/>\n      setting.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #LBA32_PR) Proffered Paper Session: Pembrolizumab<br \/>\n        (pembro) as first-line therapy for advanced\/unresectable or advanced<br \/>\n        urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052<br \/>\n        study. <\/b>A. Balar.<b> <\/b>Saturday, October 8, 9:15 \u2013 10:30 am CEST.<br \/>\n        Location: Madrid.\n      <\/li>\n<\/ul>\n<p>\n      <b>Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      At ESMO, final OS data from the phase 2 KEYNOTE-002 trial investigating\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) monotherapy compared to chemotherapy in<br \/>\n      patients with ipilimumab-refractory advanced melanoma will be presented.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>(Abstract #1107O) Proffered Paper Session: Final overall survival<br \/>\n        for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice<br \/>\n        chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.<\/b> O.<br \/>\n        Hamid. Saturday, October 8, 2:45 \u2013 4:15 pm CEST. Location: Copenhagen.\n      <\/li>\n<\/ul>\n<p>\n      <b>Additional Data from Merck\u2019s Oncology Portfolio and Pipeline<\/b>\n    <\/p>\n<p>\n      Data investigating the use of two compounds from Merck\u2019s oncology<br \/>\n      pipeline and portfolio \u2013 EMEND<sup>\u00ae<\/sup> (fosaprepitant dimeglumine),<br \/>\n      a substance P\/neurokinin-1 (NK1) receptor antagonist, and MK-2206, an<br \/>\n      investigational AKT inhibitor \u2013 were also accepted for presentation at<br \/>\n      this year\u2019s ESMO. For more information, including a complete list of<br \/>\n      abstract titles, please visit the ESMO website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcslide.ctimeetingtech.com%2Flibrary%2Fesmo%2Fbrowse%2Fitinerary%2F5286&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcslide.ctimeetingtech.com%2Flibrary%2Fesmo%2Fbrowse%2Fitinerary%2F5286&amp;index=1&amp;md5=2001c764057e30c587b7eef410dc8b0f\" rel=\"nofollow\">https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/itinerary\/5286<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1<br \/>\n      as determined by an FDA-approved test with disease progression on or<br \/>\n      after platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response. An<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%)<br \/>\n      pneumonitis and more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3;<br \/>\n      permanently discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Hepatitis occurred in 16 (1%) of 1567 patients with melanoma, including<br \/>\n      Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1567 patients with melanoma, including Grade 3<br \/>\n      (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. New or<br \/>\n      worsening hypothyroidism occurred in 28 (14.6%) of 192 patients with<br \/>\n      HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Nephritis occurred in 7 (0.4%) of 1567 patients with melanoma including,<br \/>\n      Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pleural effusion, pneumonia, dyspnea,<br \/>\n      pulmonary embolism, and pneumonitis. The most common adverse reactions<br \/>\n      (reported in at least 20% of patients) were fatigue (44%), cough (29%),<br \/>\n      decreased appetite (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue<br \/>\n      (46%), decreased appetite (22%), and dyspnea (20%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 330 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=1c0eaa00b892c97da7f018db812945d9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=9027a6fc055da4d5de1554d0e418da8c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=da30055c00885e3bebfd29fd0158a1ae\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=f8d0dfd139f1b3d03f47d0b220ef3e1a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=6546110449ce94c0bf059a9a0ab66993\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=04177ac0376735c246691eeb4ede2e0f\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=dd2d339eb34711d2aa96b9fdb1cf54ec\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=6b2b5d780b643423dbdba57046155bc5\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51429038&amp;newsitemid=20160928005651&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=1ae3b7bee79b5126f091c9f499ea7aaa\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160928005651r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Kim Hamilton,        908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 \u2013 11. In total, findings from 30 studies in 12 cancers from Merck\u2019s industry-leading clinical development program for KEYTRUDA \u2013 both as monotherapy and in combination \u2013 will be presented at this year\u2019s ESMO. Two studies of KEYTRUDA in first-line treatment of advanced lung cancer have also been selected for presentation at the Presidential Symposium on Oct. 9: KEYNOTE-024, which studied KEYTRUDA as monotherapy compared to chemotherapy in patients whose tumors express high levels of PD-L1 (tumor proportion score of 50 percent or more), and KEYNOTE-021G, which studied KEYTRUDA plus chemotherapy (carboplatin and pemetrexed) compared to chemotherapy alone in all patients with non-squamous<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745327","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 \u2013 11. In total, findings from 30 studies in 12 cancers from Merck\u2019s industry-leading clinical development program for KEYTRUDA \u2013 both as monotherapy and in combination \u2013 will be presented at this year\u2019s ESMO. Two studies of KEYTRUDA in first-line treatment of advanced lung cancer have also been selected for presentation at the Presidential Symposium on Oct. 9: KEYNOTE-024, which studied KEYTRUDA as monotherapy compared to chemotherapy in patients whose tumors express high levels of PD-L1 (tumor proportion score of 50 percent or more), and KEYNOTE-021G, which studied KEYTRUDA plus chemotherapy (carboplatin and pemetrexed) compared to chemotherapy alone in all patients with non-squamous\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\\\/\",\"name\":\"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-09-28T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/","og_locale":"en_US","og_type":"article","og_title":"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 \u2013 11. In total, findings from 30 studies in 12 cancers from Merck\u2019s industry-leading clinical development program for KEYTRUDA \u2013 both as monotherapy and in combination \u2013 will be presented at this year\u2019s ESMO. Two studies of KEYTRUDA in first-line treatment of advanced lung cancer have also been selected for presentation at the Presidential Symposium on Oct. 9: KEYNOTE-024, which studied KEYTRUDA as monotherapy compared to chemotherapy in patients whose tumors express high levels of PD-L1 (tumor proportion score of 50 percent or more), and KEYNOTE-021G, which studied KEYTRUDA plus chemotherapy (carboplatin and pemetrexed) compared to chemotherapy alone in all patients with non-squamous","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:39+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/","name":"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-09-28T05:45:00+00:00","dateModified":"2025-11-07T06:25:39+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/two-new-trials-of-mercks-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-to-be\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Two New Trials of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b200f7da-5440-4f91-8a3d-494f0f61caf0","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Two-New-Trials-of-Mercks-KEYTRUDA-pembrolizumab-as-Monotherapy-and-in-Combination-with-Chemotherapy-for-First-Line-Treatment-of-Patie-Y7YC5.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745327\/revisions"}],"predecessor-version":[{"id":3674734,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745327\/revisions\/3674734"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745327"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}